1. Definition. As used in this section, unless the context otherwise indicates, "HIV prevention drug" has the same meaning as in Title 32, section 13786-E, subsection 1, paragraph B. [PL 2025, c. 483, §1 (NEW).] 2. Reimbursement for pharmacists prescribing, dispensing and administering HIV prevention drugs. No later than January 1, 2027, the department shall provide reimbursement under the MaineCare program to a pharmacist for prescribing, dispensing and administering HIV prevention drugs under Title 32, section 13786-E. The department: A. Shall provide coverage for services provided by the pharmacist under this subsection; [PL 2025, c. 483, §1 (NEW).] B. Shall authorize a pharmacist to bill the carrier and receive direct payment for a service under this subsection that the pharmacist provides to a MaineCare member and shall identify the pharmacist as the provider in the billing and the claims process for payment of the service; and [PL 2025, c. 483, §1 (NEW).] C. May not impose on a pharmacist a practice, education or collaboration requirement that is inconsistent with or more restrictive than a requirement of state law or an agency or board rule for the pharmacist to receive payment for a service provided under this subsection. [PL 2025, c. 483, §1 (NEW).] [PL 2025, c. 483, §1 (NEW).] 3. Reimbursement model. No later than January 1, 2027, the department shall create and implement under the MaineCare program a reimbursement model to increase access to HIV prevention drugs administered under Title 32, section 13786-E. [PL 2025, c. 483, §1 (NEW).]
‹ Prev All Maine sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.